Hua Zhong

1.8k total citations · 1 hit paper
78 papers, 1.2k citations indexed

About

Hua Zhong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hua Zhong has authored 78 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Hua Zhong's work include Lung Cancer Research Studies (36 papers), Lung Cancer Treatments and Mutations (33 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Hua Zhong is often cited by papers focused on Lung Cancer Research Studies (36 papers), Lung Cancer Treatments and Mutations (33 papers) and Lung Cancer Diagnosis and Treatment (15 papers). Hua Zhong collaborates with scholars based in China, United States and Germany. Hua Zhong's co-authors include Baohui Han, Runbo Zhong, Jianlin Xu, Tianqing Chu, Yanwei Zhang, Yan Zhou, Yuqing Lou, Chunlei Shi, Xueyan Zhang and Jiajun Teng and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Hua Zhong

74 papers receiving 1.2k citations

Hit Papers

Phase 1b Study of Sintilimab Plus Anlotinib as First-line... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    2021 174 citations Tianqing Chu, Runbo Zhong et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hua Zhong China 19 723 553 303 193 168 78 1.2k
Dorothee Gramatzki Switzerland 19 335 0.5× 345 0.6× 444 1.5× 343 1.8× 154 0.9× 59 1.4k
Masayuki Tanahashi Japan 19 521 0.7× 459 0.8× 517 1.7× 229 1.2× 74 0.4× 97 1.3k
Noah Berkowitz United States 18 466 0.6× 386 0.7× 452 1.5× 101 0.5× 63 0.4× 41 1.8k
Vei Mah United States 20 507 0.7× 390 0.7× 927 3.1× 236 1.2× 116 0.7× 38 1.7k
Patricia M.M.B. Soetekouw Netherlands 20 378 0.5× 424 0.8× 782 2.6× 348 1.8× 44 0.3× 46 1.3k
Justin Bottsford-Miller United States 16 591 0.8× 163 0.3× 559 1.8× 324 1.7× 60 0.4× 42 1.4k
Hendrik Seeliger Germany 24 902 1.2× 508 0.9× 609 2.0× 235 1.2× 110 0.7× 64 1.8k
Mark Rosenblum United States 13 285 0.4× 504 0.9× 474 1.6× 160 0.8× 150 0.9× 17 1.8k
Marinus A. Noordzij Netherlands 17 296 0.4× 988 1.8× 625 2.1× 282 1.5× 139 0.8× 29 1.4k
Zhen Zhao China 17 388 0.5× 194 0.4× 353 1.2× 182 0.9× 78 0.5× 39 956

Countries citing papers authored by Hua Zhong

Since Specialization
Citations

This map shows the geographic impact of Hua Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hua Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hua Zhong more than expected).

Fields of papers citing papers by Hua Zhong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hua Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hua Zhong. The network helps show where Hua Zhong may publish in the future.

Co-authorship network of co-authors of Hua Zhong

This figure shows the co-authorship network connecting the top 25 collaborators of Hua Zhong. A scholar is included among the top collaborators of Hua Zhong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hua Zhong. Hua Zhong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luo, Jie, et al.. (2024). CircAGFG1 Promotes Ovarian Cancer Progression Through the miR-409-3 p/ZEB1 Axis. Technology in Cancer Research & Treatment. 23. 2233994311–2233994311. 5 indexed citations
2.
Zhong, Hua, Rong Zhong, Rui Qiao, et al.. (2024). 649P Phase I study of SHR-A2102, a nectin-4 targeted ADC, in patients with advanced solid tumors. Annals of Oncology. 35. S513–S513. 1 indexed citations
3.
Lü, Jun, Huiping Qiang, Mingfang Lu, et al.. (2023). Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity via Immunogenic Cell Death and Macrophage Reprogramming. Advanced Therapeutics. 6(11). 5 indexed citations
4.
Zhang, Wei, Jing Wang, Qiming Wang, et al.. (2023). A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer. Lung Cancer. 184. 107353–107353. 7 indexed citations
5.
6.
Hu, Yaohua, Jianlin Xu, Rong Qiao, et al.. (2023). Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy. International Journal of Cancer. 153(3). 635–643. 21 indexed citations
7.
Lou, Yuqing, Jun Lü, Yanwei Zhang, et al.. (2022). The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma. Cancer Letters. 532. 215599–215599. 13 indexed citations
8.
Nie, Wei, Guangyu Tao, Jie Qian, et al.. (2022). Prognostic and predictive value of radiomic signature in stage I lung adenocarcinomas following complete lobectomy. Journal of Translational Medicine. 20(1). 339–339. 4 indexed citations
9.
Nie, Wei, Zhijie Wang, Kai Zhang, et al.. (2022). ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. BMC Medicine. 20(1). 170–170. 22 indexed citations
10.
11.
Xu, Jianlin, et al.. (2021). Patterns of Recurrence and Survival Rate After Complete Resection of Pathological Stage N2 Small-Cell Lung Cancer. Frontiers in Oncology. 11. 675354–675354. 3 indexed citations
12.
Han, Baohui, Tianqing Chu, X. Zhang, et al.. (2019). P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 14(10). S398–S398. 5 indexed citations
13.
Han, Baohui, Tianqing Chu, Runbo Zhong, et al.. (2019). JCSE01.11 Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S129–S129. 15 indexed citations
14.
Li, Yuan, Steven R. McGreal, Jean J. Zhao, et al.. (2016). A cell-based quantitative high-throughput image screening identified novel autophagy modulators. Pharmacological Research. 110. 35–49. 47 indexed citations
15.
Ma, Meili, Chunlei Shi, Jialin Qian, et al.. (2016). Comparison of plasma and tissue samples in epidermal growth factor receptor mutation by ARMS in advanced non-small cell lung cancer. Gene. 591(1). 58–64. 31 indexed citations
16.
Shen, Xinhua, Yanfeng Wu, Xiaoquan Wang, et al.. (2014). Association analysis of COMT/MTHFR polymorphisms and major depressive disorder in Chinese Han population. Journal of Affective Disorders. 161. 73–78. 30 indexed citations
17.
Chu, Tianqing, Jiajun Teng, Liyan Jiang, Hua Zhong, & Baohui Han. (2013). Lung cancer-derived Dickkopf1 is associated with bone metastasis and the mechanism involves the inhibition of osteoblast differentiation. Biochemical and Biophysical Research Communications. 443(3). 962–968. 26 indexed citations
18.
Zhong, Hua, et al.. (2013). Relationship Between HBV Genotypes B, C and Follicular Helper T Cells in Patients with Chronic Hepatitis B and its Significance. Hepatitis Monthly. 13(1). e6221–e6221. 11 indexed citations
19.
Zhong, Hua, Ziyuan Zhou, Huan Wang, et al.. (2012). Prevalence of Cutaneous Adverse Drug Reactions in Southwest China: An 11-Year Retrospective Survey on In-patients of a Dermatology Ward. Dermatitis. 23(2). 81–85. 13 indexed citations
20.
Zhong, Hua, et al.. (2012). Research on Hydraulic Soil Slope Frost Heaving Damage Model Test. Applied Mechanics and Materials. 256-259. 422–426. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dorothee Gramatzki Breakdown of academic impact, for papers by Masayuki Tanahashi Breakdown of academic impact, for papers by Noah Berkowitz Breakdown of academic impact, for papers by Vei Mah Breakdown of academic impact, for papers by Patricia M.M.B. Soetekouw Breakdown of academic impact, for papers by Justin Bottsford-Miller Breakdown of academic impact, for papers by Hendrik Seeliger Breakdown of academic impact, for papers by Mark Rosenblum Breakdown of academic impact, for papers by Marinus A. Noordzij Breakdown of academic impact, for papers by Zhen Zhao
Rankless by CCL
2026